Last reviewed · How we verify
Migraine without aura — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Zavzpret | zavegepant | Pfizer | CGRP receptor antagonist | Calcitonin gene-related peptide (CGRP) receptor | 2023-01-01 | |
| Zavzpret | Zavegepant Hydrochloride | Pfizer | Calcitonin Gene-related Peptide Receptor Antagonist | Calcitonin gene-related peptide type 1 receptor | 2023-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Migraine without aura
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Migraine without aura:
- Migraine without aura treatment updates — RSS
- Migraine without aura treatment updates — Atom
- Migraine without aura treatment updates — JSON
Cite this brief
Drug Landscape (2026). Migraine without aura — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/migraine-without-aura. Accessed 2026-06-10.
Related
- Migraine without aura full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing